[Immunopathogenesis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)]

Brain Nerve. 2018 Jan;70(1):35-40. doi: 10.11477/mf.1416200947.
[Article in Japanese]

Abstract

A recent study on the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has revealed an elevation of inflammatory and anti-inflammatory cytokines in the sera and cerebrospinal fluids of the patients and presence of autoantibodies in subgroups of ME/CFS patients. Furthermore, investigator-initiated clinical trials have proved the efficacy of anti-CD20 antibody (rituximab), that eliminate B cells, in the treatment of ME/CFS. Based on these findings, we hypothesize that immune abnormalities, such as enhanced autoimmune responses, may play an essential role in the neuroinflammatory pathogenesis of ME/CFS.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / immunology
  • Cytokines / immunology
  • Fatigue Syndrome, Chronic / immunology*
  • Female
  • Gastrointestinal Microbiome
  • Humans
  • Killer Cells, Natural / immunology
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Autoantibodies
  • Cytokines